Kinex News
Back to headlines
May 27, 2009
Kinex Phase 1 Clinical Data Selected as "Best of ASCO"
Kinex Pharmaceuticals will present results from a Phase 1 clinical study with KX2-391, at the ASCO 2009 Annual Meeting in Orlando, on May 29, 2009. The study was carried out at MD Anderson, Roswell Park Cancer Institute (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, the Principal Investigator from RPCI will deliver the presentation entitled “Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies.
The presentation will provide data from this multi-center Phase 1 trial that utilized the standard 3+3 design to determine the Maximum Tolerated Dose (MTD), safety, and pharmacokinetics (PK) of KX2-391 in patients with refractory solid tumors. Patients who responded to treatment will be highlighted.
This presentation was designated as Best of ASCO® which features high-impact abstracts from the 2009 ASCO Annual Meeting that represent the most relevant, cutting-edge science in oncology today. This information has been selected to be presented at meetings in the US and internationally because it highlights the latest scientific findings in primary disease sites and practice-changing advances in cancer prevention and treatment.
Kinex Pharmaceuticals is a drug discovery and development company that is focused on next generation drugs to treat cancer and immuno-inflammatory diseases. The Company has utilized its platform technologies to identify highly selective inhibitors of therapeutically relevant targets that are involved in signal transduction and cell cycle control.